EUVIMEDSkopri EUVIMED
Crossref

Multigene Methylation Analysis of Gastrointestinal Tumors

Silvia Sabbioni, Elena Miotto, Angelo Veronese, Elisa Sattin, Laura Gramantieri, Luigi Bolondi, George A Calin, Roberta Gafà, Giovanni Lanza, Giuliano Carli, Eros Ferrazzi, Carlo Feo and 3 more

Molecular Diagnosis · 2003

DOI: 10.1007/bf03260039 ↗

At a glance

Journal article in Molecular Diagnosis, 2003. Written by Silvia Sabbioni and 14 co-authors. Institution: Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy. Major MEDLINE topics: DNA Methylation. Cited 4 times so far (Crossref); 31 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

BACKGROUND: Gene promoter methylation is a mechanism for tumor suppressor gene silencing and inactivation. The development of highly sensitive methods for revealing aberrant cancer-associated DNA methylation allows the identification of tumor markers not only in tumor samples, but also in body fluid, an approach that can be useful in the early detection of neoplasms. METHODS: We analyzed the methylation status at 16 loci in tumor samples of the gastrointestinal tract and in early or pre-neoplastic lesions of the colon. RESULTS: Tumor samples revealed that methylation at the transmembrane protein containing epidermal growth factor and follistatin domains (TPEF) locus had the best ratio of discrimination between tumor samples versus normal tissues (83 versus 0%). Its combination with hypermethylated in cancer 1 (HIC1), death-associated protein kinase (DAPK) and O-6-methylguanine DNA methyltransferase (MGMT), allowed the detection of aberrant methylation in 98% of colorectal carcinomas and 100% of gastric carcinomas. The same alterations were also detected in colon adenomas and tissues surrounding the adenomas, indicating that hypermethylation at these loci occurred early in tumor progression. Analysis of DNA from peripheral blood revealed that TPEF methylation was detectable in colorectal tumor patients and patients with early or pre-neoplastic lesions, but not in healthy volunteers. CONCLUSIONS: Our results identify TPEF as a tumor marker that could be useful in the follow-up of gastrointestinal cancer patients or the screening of individuals at risk of developing gastrointestinal neoplasms.

Subjects

MeSH terms (MEDLINE)

DNA MethylationAdenomaColonic NeoplasmsDNA, NeoplasmGastrointestinal NeoplasmsHumansMultigene FamilyPromoter Regions, GeneticStomach Neoplasms

Substances

DNA, Neoplasm

Authors and institutions

  • Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy.

Cite

APA

Sabbioni, S., Miotto, E., Veronese, A., Sattin, E., Gramantieri, L., Bolondi, L., Calin, G. A., Gafà, R., Lanza, G., Carli, G., Ferrazzi, E., Feo, C., Liboni, A., Gullini, S., & Negrini, M. (2003). Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis. https://doi.org/10.1007/bf03260039

Vancouver

Sabbioni S, Miotto E, Veronese A, Sattin E, Gramantieri L, Bolondi L, et al. Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis. 2003. doi:10.1007/bf03260039

BibTeX
@article{Sabbioni2003,
  author = {Sabbioni, Silvia and Miotto, Elena and Veronese, Angelo and Sattin, Elisa and Gramantieri, Laura and Bolondi, Luigi and Calin, George A and Gafà, Roberta and Lanza, Giovanni and Carli, Giuliano and Ferrazzi, Eros and Feo, Carlo and Liboni, Alberto and Gullini, Sergio and Negrini, Massimo},
  title = {Multigene Methylation Analysis of Gastrointestinal Tumors},
  journal = {Molecular Diagnosis},
  year = {2003},
  doi = {10.1007/bf03260039}
}
Start for free →